- PMC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.3 million.
- PMC is making at least a new 3-day high.
- PMC has a PE ratio of 130.3.
- PMC is mentioned 0.77 times per day on StockTwits.
- PMC has not yet been mentioned on StockTwits today.
- PMC is currently in the upper 20% of its 1-year range.
- PMC is in the upper 35% of its 20-day range.
- PMC is in the upper 45% of its 5-day range.
- PMC is currently trading above yesterday's high.
'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in PMC with the Ticky from Trade-Ideas. See the FREE profile for PMC NOW at Trade-IdeasMore details on PMC: PharMerica Corporation operates as an institutional pharmacy services company in the United States. The company offers services to healthcare facilities; pharmacy management services to hospitals; specialty infusion services to patients outside hospitals; and oncology pharmacy services. PMC has a PE ratio of 130.3. Currently there are 4 analysts that rate Pharmerica a buy, 1 analyst rates it a sell, and 1 rates it a hold. The average volume for Pharmerica has been 357,200 shares per day over the past 30 days. Pharmerica has a market cap of $864.2 million and is part of the services sector and retail industry. The stock has a beta of 1.23 and a short float of 6% with 5.20 days to cover. Shares are up 41.5% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Pharmerica as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
Highlights from the ratings report include:
- Despite its growing revenue, the company underperformed as compared with the industry average of 18.9%. Since the same quarter one year prior, revenues rose by 16.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The debt-to-equity ratio is somewhat low, currently at 0.73, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.30, which illustrates the ability to avoid short-term cash problems.
- Net operating cash flow has significantly increased by 1272.97% to $50.80 million when compared to the same quarter last year. In addition, PHARMERICA CORP has also vastly surpassed the industry average cash flow growth rate of 54.82%.
- PHARMERICA CORP's earnings per share declined by 33.3% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, PHARMERICA CORP reported lower earnings of $0.22 versus $0.63 in the prior year. This year, the market expects an improvement in earnings ($1.62 versus $0.22).
- Compared to where it was 12 months ago, the stock is up, but it has so far lagged the appreciation in the S&P 500. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that the other strengths this company displays justify these higher price levels.
- You can view the full Pharmerica Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.